Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Active Biotech in its new issue
Mandate

Vinge advises Active Biotech in its new issue

April 06, 2009

Vinge has advised Active Biotech in its new issue of shares subject to pre-emption rights for the existing shareholders. Under the new issue, which is underwritten in its entirety by the principal shareholders MGA Holding and Nordstjernan, Active Biotech receives approximately SEK 256 million.

Vinge’s team was led by Erik Sjöman who was assisted by, among others, associates Christian Lindhé, Karolina Tjärnberg Jansson and Maria Doeser (tax law advice).

Related

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026

Vinge has advised IK Partners in connection with the acquisition of Selatek

 Vinge has advised IK Partners (“IK”) in connection with IK X Fund’s acquisition of SELATEK Holding AB (“Selatek”), a leading Swedish technical installation platform, from Amplio Private Equity AB and the minority shareholders.
April 20, 2026

Vinge advises Right Side Group, a portfolio company of Alder, in connection with the acquisition of Brandkonsultbyrån i Sverige

 Brandkonsultbyrån in Sweden is a technical consultant specialising in structural fire protection, evacuation safety and risk management. The acquisition strengthens the group’s position as a leading player in fire, risk and safety in the Nordic region.
April 17, 2026